1-3 of 3
E Paul Wileyto
Close
Sort by
Journal Articles

A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, MD, Yulia Nefedova, MD PhD, E. Paul Wileyto, PhD, Harjeet Sembhi, Inna Strakovsky, MPH, MRA, Chau Nguyen, Rimzim Taneja, Eva Bondesson, PhD, Helena Eriksson, PhD, Helen Tuvesson, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137482
Published: 2020
Journal Articles

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Jie Wang, MD, Jennifer J.D. Morrissette, PhD, E. Paul Wileyto, PhD, Stephen J. Schuster, MD, Alexandra Vandegrift, BA, Allison Rago, BSN, Colleen Dorsey, BSN, David Porter, MD, Daniel J. Landsburg, MD, Prioty Islam, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Scott Weber, BS, Edward A. Stadtmauer, MD, Anthony Mato, MD
Journal: Blood
Blood (2015) 126 (23): 2929.
https://doi.org/10.1182/blood.V126.23.2929.2929
Published: 2015
Journal Articles

A Single-Center Retrospective Comparison of Post-Transplant Outcomes in Patients Receiving VRD Vs. VD Vs. RD As Initial Therapy Prior to ASCT for Newly Diagnosed Multiple Myeloma (MM)

Nathan C Nussbaum, MD, Andrew Dougherty, Dan T. Vogl, MD, MSCE, Brendan M Weiss, MD, David L Porter, MD, E Paul Wileyto, Kathleen Cunningham, Patricia A. Mangan, Brenda K. Shelly, Heather DiFilippo, Edward A. Stadtmauer, MD
Journal: Blood
Blood (2012) 120 (21): 2042.
https://doi.org/10.1182/blood.V120.21.2042.2042
Published: 2012